This week's clinical trial failures for colchicine, several monoclonal antibodies, and other drugs that have been tried with initial enthusiasm which then crashes to earth when it is discovered that anti-malaria drugs, gout drugs, and other re-purposed medications simply don't work --
means that the bar for efficacy is very low for therapeutic drugs that have any kind of meaningful effect.

Given Brilacidin's fantastic safety profile, which is much better than these other drugs, there should be no problems along that line either. Its success in other clinical trials makes me extremely optimistic for this one.